Many immunocompromised patients suffer from pulmonary and central
nervous system fungal infections caused by pathogens such as C. neoformans. The current standard
treatment entails intravenously administrating anti-fungal agents that are
extremely toxic. In addition, new structural and mechanistic classes of
antifungal therapeutics are needed to improve treatment options and to counter
increasing resistance to currently used agents. This invention identifies and
validates a novel treatment regime entailing a combination of two drugs.
Dr. Damian Krysan of the URMC has found that a combined therapy of
a known antifungal agent and an FDA approved metastatic breast cancer drug are a
much better and more powerful treatment regimen against fungal infections.
Furthermore, this regimen has the potential to be used prophylactically in
patients at risk of infection.
Current therapy has major risks including toxic side effects and is
given intravenously. This combination of drugs is at low doses and can be given
orally. Most addition, both drugs involved in this combination therapy are FDA
approved so the path to clinical approval is significantly reduced.